Schistosomiasis Clinical Trial
— NIDIAGDigestOfficial title:
Diagnosis of Neglected Tropical Diseases (NTDs) in Patients Presenting With Persistent Digestive Disorders (≥2 Weeks) in Côte d'Ivoire, Indonesia, Mali and Nepal
NIDIAG is an international collaboration on integrated diagnosis-treatment platforms, funded
by the European Commission (EC). NIDIAG aims to develop an improved, patient-centred system
for delivering primary health care in resource-constrained settings. NIDIAG will investigate
three clinical syndromes, namely (i) persistent digestive disorders, (ii) persistent fever
and (iii) neurological disorders, due to neglected tropical diseases (NTDs). The current
study focuses on persistent digestive disorders, which are defined as diarrhoea or abdominal
pain that last for at least 2 weeks.
While acute diarrhoea has been studied globally, few research activities have focused on the
epidemiology, diagnosis and treatment of long-lasting diarrhoeal episodes (2 weeks and
longer) in the tropics. The spectrum of possibly involved pathogens includes more than 30
bacterial, parasitic and viral infectious agents. This lack of data may be explained by the
fact that people suffering from NTDs might only seek care at a late stage of the disease.
Furthermore, health systems in affected regions are often weak and their primary health-care
centres are often under-staffed and lack essential diagnostic equipment.
The hypothesis of this study is that development of an evidence-based syndromic approach can
lead to better diagnosis and management of NTDs in patients with persistent digestive
disorders. The study will be carried out in two West African countries (Côte d'Ivoire and
Mali) and in two Asian countries (Indonesia and Nepal). The study will follow a
"case-control" design and patients and controls will be prospectively enrolled. In order to
address the knowledge gaps, three specific objectives will be pursued. First, the
contribution of NTDs to the 'persistent digestive disorders syndrome' will be assessed.
Second, the value of clinical features and rapid diagnostic tests (RDTs) for the diagnosis
of target NTDs that give rise to persistent digestive disorders will be determined. Third,
the clinical response to standard empiric and targeted treatment of several NTDs in patients
with persistent digestive disorders will be evaluated. These objectives will provide a
long-term benefit for the communities by improving the clinical decision-making process for
the target NTDs and thus, better diagnostic work-up and patient management can be achieved
in the study countries and other similar resource-constrained countries
Status | Completed |
Enrollment | 2800 |
Est. completion date | May 2016 |
Est. primary completion date | March 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 1 Year and older |
Eligibility |
Inclusion Criteria: 1. Individuals aged =1 year presenting with persistent diarrhoea (=3 loose stools per days for =2 weeks; symptomatic group) and/or children (aged 1-18 years) with persistent abdominal pain (localized or diffuse abdominal pain lasting for =2 weeks, with possible intermittence/recurrence). 2. Individuals with written informed consent provided. Exclusion Criteria: 1. Individuals in need of immediate intensive or surgical care. 2. Individuals who are unable or unwilling to give written informed consent. 3. Individuals who do not meet the inclusion criteria for being a case or control (e.g. people with acute diarrhoea). 4. Individuals with clinical jaundice (assessed by direct observation of the conjunctivae). 5. Individuals who are unable, in the study physician's opinion, to comply with the study requirements. 6. Individuals who are already participating in other ongoing diagnostic studies and/or clinical trials. |
Observational Model: Case Control, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Côte D'Ivoire | Hôpital Méthodiste de Dabou | Dabou | |
Indonesia | Tulehu health center | Maluku Tengah | Maluku |
Indonesia | Tulehu hospital | Maluku Tengah | Maluku |
Mali | Institut National de Recherche en Santé Publique | Bamako | |
Mali | Niono District Reference Health Centre | Niono | |
Nepal | Dhankuta District Hospital | Dhankuta | |
Nepal | B.P. Koirala Institute of Health Sciences | Dharan |
Lead Sponsor | Collaborator |
---|---|
Swiss Tropical & Public Health Institute | B.P. Koirala Institute of Health Sciences, Gadjah Mada University, Institut National de Recherche en Santé Publique, Institute of Tropical Medicine, Belgium, Université Félix Houphouët-Boigny |
Côte D'Ivoire, Indonesia, Mali, Nepal,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Prevalence of neglected tropical diseases (NTDs) causing persistent digestive disorders (=2 weeks) | The frequency, distribution, and if possible, intensity of target NTDs | 18 months | No |
Secondary | Sensitivity, specificity, crude and adjusted likelihood ratios (LR) and predictive values (post-test probabilities) of clinical features and laboratory tests for the diagnosis of target NTDs | 18 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04115072 -
Treatment of Female Genital Schistosomiasis (FGS) With Praziquantel: A Proof-of-Concept Study
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT05999825 -
Sm-p80 Schistosomiasis Challenge Study
|
Phase 2 | |
Completed |
NCT00463931 -
Using Community-Based Volunteers to Reach Non-Enrolled School Aged Children Through Community-Directed Treatment of Schistosomiasis in School-Aged Children in Rural Northern Ghana
|
N/A | |
Completed |
NCT00276224 -
Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia
|
N/A | |
Completed |
NCT00215267 -
The Effect of Praziquantel Treatment on Schistosoma Mansoni Morbidity and re-Infection Along Lake Victoria, Uganda
|
N/A | |
Completed |
NCT03845140 -
L-PZQ ODT in Schistosoma Infected Children
|
Phase 3 | |
Completed |
NCT01512277 -
Clinical Trial of Bilhvax,a Vaccine Candidate Against Schistosomiasis
|
Phase 1 | |
Active, not recruiting |
NCT03910972 -
Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults
|
Phase 1/Phase 2 | |
Completed |
NCT05085470 -
Repeated Controlled Human Schistosoma Mansoni Infection
|
N/A | |
Completed |
NCT02755324 -
Single-sex Controlled Human Schistosomiasis Infection: Safety and Dose Finding
|
N/A | |
Recruiting |
NCT05868005 -
Delivering a Multi-disease Screening Tool to Migrant Populations
|
N/A | |
Active, not recruiting |
NCT01869465 -
Evaluation of Strategies for Improved Uptake of Preventive Treatment for Intestinal Schistosomiasis
|
N/A | |
Completed |
NCT01553552 -
Schistosomiasis Effect on Response to Vaccines, Anaemia and Nutritional Status of Children of Northern Senegal
|
N/A | |
Recruiting |
NCT04589390 -
Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension
|
Phase 2 | |
Completed |
NCT02868385 -
Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST)
|
Phase 3 | |
Recruiting |
NCT05762393 -
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Sm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar
|
Phase 1 | |
Not yet recruiting |
NCT06182176 -
Effectiveness and Cost-effectiveness of Integrated Model for Malaria and Helminth Control
|
N/A | |
Completed |
NCT05292391 -
Safety, Tolerability, and Immunogenicity Study of Sm-p80 + GLA-SE (SchistoShield(R)) Vaccine in Healthy Adults
|
Phase 1 | |
Completed |
NCT03110757 -
A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel)(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults
|
Phase 1 | |
Completed |
NCT01154049 -
Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis
|
Phase 1 |